References
1. Yona S., Kim K.W., Wolf Y., Mildner A., et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013; 38 (1): 78-91. doi: 10.1016/j.immuni.2012.12.001.
2. Ginhoux F., Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 2014; 14 (6): 392-404. doi: 10.1038/nri3671.
3. Goswami K.K., Ghosh T., Ghosh S., Sarkar M., et al. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Cell. Immunol. 2017; 316: 1-10. doi: 10.1016/j.cellimm.2017.04.005.
4. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141 (1): 39-51. doi: 10.1016/j.cell.2010.03.014.
5. Elgert K.D., Alleva D.G., Mullins D.W. Tumor-induced immune dysfunction: macrophage connection. J. Leukoc. Biol. 1998; 64: 275-90.
6. Dwyer A.R., Greenland E.L., Pixley F.J. Promotion of tumor invasion by tumor-associated macrophages: the role of CSF-1- activated phosphatidylinisitol 3 kinase and Src family kinase motility signaling. Cancer (Basel). 2017; 9 (6). pii: E68. doi: 10.3390/cancers9060068.
7. Hagemann T., Robinson S.C., Schulz M., Trümper L., et al. Enhanced invasiveness of breast cancer cell lines upon cocultivation with macrophages is due to TNF-αdependent up regulatijn of matrix metalloproteses. Carcinogenesis. 2004; 25: 1543-9. doi: 10.1093/carcin/bgh146.
8. Goswami S., Sahai E., Wyckoff J.B., Cammer M., et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res. 2005; 65 (12): 5278-83. doi: 10.1158/0008-5472.CAN-04-1853.
9. Kluger H.M., Dolled-Filhart M., Rodov S., Kacinski B.M., et al. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin. Cancer Res. 2004; 10 (1 Pt 1): 173-7. doi: 10.1158/1078-0432.CCR-0699-3.
10. Zhu Y., Knolhoff B.L., Meyer M.A. CSF-1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014; 74 (18): 5057-69. doi: 10.1158/0008-5472.CAN-13-3723.
11. Hatanaka H., Abe Y., Kamlya T., Morino F., et al. Clinical implication of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann. Oncol. 2000; 9 (5): 815-9. doi: 10.1023/a:1008375208574.
12. Hoeffel G., Ginhoux F. Fetal monocytes and the origins of tissue-resident macrophages. Cell. Immunol. 2018; 330: 5-15. doi: 10.1016/j.cellimm.2018.01.001.
13. Zhao Y., Zou W., Du J., Zhao Y. The origins and homeostasis of monocytes and tissue-resident macrophages in physiological situation. J. Cell. Physiol. 2018; 233 (10): 6425-39. doi: 10.1002/jcp.26461.
14. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66 (2): 605-12. doi: 10.1158/0008-5472.CAN-05-4005.
15. Murray P.J. Macrophage polarization. Annu. Rev. Physiol. 2017; 10 (79): 541-66. doi: 10.1146/annurev-physiol-022516-034339.
16. Mantovani A., Biswas S.K., Galdiero M.R., Sica A., et al. Macrophage plasticity and polarization in tissue repair and remodeling. J. Pathol. 2013; 229 (2): 176-85. doi: 10.1002/path.4133.
17. Porta C., Riboldi E., Ippolito A., Sica A. Molecular and epigenetic basis of macrophage polarized activation. Semin. Immunol. 2015; 27 (4): 237-48. doi: 10.1016/j.smim.2015.10.003.
18. Liu Y., Can X. The origin and function of tumor-associated macrophages. Cell. Mol. Immunol. 2015; 12 (1): 1-4. doi: 10.1038/cmi.2014.83.
19. Mantovani A., Sozzani S., Locati M., Allavena P., et al. Macrophage polarization : tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends. Immunol. 2002; 23 (11): 549-55. doi: 10.1016/S1471-4906(02)02302-5.
20. Heusinkveld M., van der Burg S.H. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 2011; 16 (9): 216. doi: 10.1186/1479-5876-9-216.
21. Lin E.Y., Pollard J.W. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007; 67 (11): 5064-6. doi: 10.1158/0008-5472.CAN-07-0912.
22. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141 (1): 52-67. doi: 10.1016/j.cell.2010.03.015.
23. Valkovic T., Dobrila F., Melato M., Sasso F., et al. Correlation between vascular endothelial growth factor, angiogenesis and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch. 2002; 440 (6): 583-8. doi: 10.1007/s004280100458.
24. Elbarghati L., Murdoch C., Lewis C.E. Effects of hypoxia on transcription factor expression in human monocytes and macrophages. Immunobiology. 2008; 213 (9-10): 899-908. doi: 10.1016/j.imbio.2008.07.016.
25. Nieves B.J., D’Amore P.A., Bryan B.A. The function of vascular endothelial growth factor. Biofactors 2009; 35 (4): 332-7. doi: 10.1002/biof.46.
26. Yeo E.J., Cassetta L., Qian B.Z., Lewkowich I., et al. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. Cancer Res. 2014; 74 (11): 2962-73. doi: 10.1158/0008-5472.CAN-13-2421.
27. Wickoff J.B., Wang Y., Lin E.Y., Li J.F., et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007; 67 (6): 2649-56. doi: 10.1158/0008-5472.CAN-06-1823.
28. De Palma M., Naldini L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin. Cancer Res. 2011; 17 (16): 5226-32. doi: 10.1158/1078-0432.CCR-10-0171.
29. Decock J., Thirkettle S., Wagstaff L., Edwards D.R. Matrix metalloproteinases: protective roles in cancer. J. Cell. Mol. Med. 2011; 15 (6): 1254-65. doi: 10.1111/j.1582-4934.2011.01302.x
30. Deryugina E.I., Zajac E., Juncker-Jensen A., Kupriyanova T.A., et al. Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia. 2014; 16 (10): 771-88. doi: 10.1016/j.neo.2014.08.013.
31. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion and metastasis. Cell. 2006; 124 (2): 263-6. doi: 10.1016/j.cell.2006.02.007.
32. Smith H.A., Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J. Mol. Med. (Berl.). 2013; 91 (4): 411-29. doi: 10.1007/s00109-013-1021-5.
33. Nielsen S.R., Schmid M.C. Macrophages as key drivers of cancer progression and metastasis. Mediators Inflamm. 2017; 2017: 9624760. doi: 10.1155/2017/9624760.
34. Guo Q., Jin Z., Yuan Y., Liu R., et al. New mechanisms of tumor-associated macrophages on promoting tumor progression: recent research advances and potential targets for tumor immunotherapy. J. Immunol. Res. 2016; 2016: 9720912. doi: 10.1155/2016/9720912.
35. Desai A., Yan Y., Gerson S.L. Concise reviews: cancer stem cell targeted therapies: toward clinical success. Stem Cells Transl. Med. 2019; 8 (1): 75-81. doi: 10.1002/sctm.18-0123.
36. Croci D.O., Salatino M. Tumor immune escape mechanisms that operate during metastasis. Curr. Pharm. Biotechnol. 2011; 12 (11): 1923-36.
37. Киселевский М.В., Власенко Р.Я., Заботина Т.Н.. Кадагидзе З.Г. Прогностическая значимость опухоль-инфильтрирующих лимфоцитов. Иммунология. 2019; 40 (1): 73-82. doi: 10.24411/0206-4952-2019-11009.[Kiselevskiy M.V., Vlasenko R.Ya., Zabotina T.N., Kadagidze Z.G. Prognostic significance of tumor-infiltrating lymphocytes. Immunologiya. 2019; 40 (1): 73-82. (in Russian)]
38. Petty A.J., Yang Y. Tumor-associated macrophages: implication in cancer immunotherapy. Immunotherapy. 2017; 9 (3): 289-302. doi: 10.2217/imt-2016-0135.
39. Curiel T.J., Coukos G., Zou L., Alvarez X., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predict reduced survival. Nat. Med. 2004; 10 (9): 942-9. doi: 10.1038/nm1093.
40. Ng T.H., Britton G.J., Hill E.V., Verhagen J., et al. Regulation of adaptive immunity; the role of interleukin-10. Front. Immunol. 2013; 4: 129. doi: 10.3389/fimmu.2013.00129.
41. Kuang D.M., Zhao Q., Peng C., Xu J., et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 2009; 206 (6): 1327-37. doi: 10.1084/jem.20082173.
42. Dewan M.Z., Vanpouille-Box C., Kawashima N., DiNapoli S., et al. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin. Cancer Res. 2012; 18 (24): 6668-78. doi: 10.1158/1078-0432.CCR-12-0984.
43. Singh M., Khong H., Dai Z., Huang X.F., et al. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. J. Immunol. 2014; 193 (9): 4722-31. doi: 10.4049/jimmunol.1401160.
44. Buhtoiarov I.N., Lum H., Berke G., Sondel P.M., et al. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J. Immunol. 2006; 176 (1): 309-18. doi: 10.4049/jimmunol.176.1.309.
45. Buhtoiarov I.N., Sondel P.M., Wigginton J.M., Buhtoiarova T.N., et al. Antitumor synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumor associated macrophages. Immunology 2011; 132 (2): 226-39. doi: 10.1111/j.1365-2567.2010.03357.x.
46. Rakhmilevich A.L., Baldeshwiler M.J., Van De Voort T.J., Felder M.A.R., et al. Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol. Immunother. 2012; 61: 1683-97. doi: 10.1007/s00262-012-1236-2.
47. Kubota Y., Takubo K., Shimizu T., Ohno H., et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J. Exp. Med. 2009; 206 (5): 1089-102. doi: 10.1084/jem.20081605.
48. Strachan D.C., Ruffell B., Oei Y., Bissell M.J., et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells. Oncoimmunology. 2013; 2 (12): e26968. doi: 10.4161/onci.26968.
49. Cannarile M.A., Weisser M., Jacob W., Jegg A.M., et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer. 2017; 5 (1): 53. doi: 10.1186/s40425-017-0257-y.
50. Li X., Yao W., Yuan Y., Chen P., et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017; 66 (1): 157-67. doi: 10.1136/gutjnl-2015-310514.